Ad is loading...
MENU

PHAT Stock Phathom Pharmaceuticals (PHAT, $13.04) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 11, 2024

A.I.dvisor
at Tickeron.com
Loading...
PHAT - Phathom Pharmaceuticals
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $13.04
Daily change: -$3.82 (-22.66%)
Daily volume: 4.5M
Capitalization: $891.6M
Industry: Biotechnology
This is a Bearish indicator signaling PHAT's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 54 similar cases where PHAT's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

PHAT sees MACD Histogram crosses below signal line

PHAT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 11, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 54 instances where the indicator turned negative. In of the 54 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on PHAT as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

PHAT moved below its 50-day moving average on November 08, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PHAT crossed bearishly below the 50-day moving average on November 12, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAT advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .

PHAT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 171 cases where PHAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PHAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.849). P/E Ratio (0.000) is within average values for comparable stocks, (95.928). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). PHAT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (19.960) is also within normal values, averaging (211.128).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PHAT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
100 Campus Drive
Phone
+1 877 742-8466
Employees
452
Web
https://www.phathompharma.com